| Autor: |
Schmidt LK; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA., Orne CE; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA., Shaffer TL; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA., Wilson SM; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Khakhum N; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Torres AG; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Brett PJ; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.; Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand., Burtnick MN; Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.; Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. |
| Abstrakt: |
Burkholderia pseudomallei, the causative agent of melioidosis, is a facultative intracellular, Gram-negative pathogen that is highly infectious via the respiratory route and can cause severe, debilitating, and often fatal diseases in humans and animals. At present, no licensed vaccines for immunization against this CDC Tier 1 select agent exist. Studies in our lab have previously demonstrated that subunit vaccine formulations consisting of a B. pseudomallei capsular polysaccharide (CPS)-based glycoconjugate (CPS-CRM197) combined with hemolysin-coregulated protein (Hcp1) provided C57BL/6 mice with high-level protection against an acute inhalational challenge of B. pseudomallei. In this study, we evaluated the immunogenicity and protective capacity of B. pseudomallei alkyl hydroperoxide reductase subunit C (AhpC) in combination with CPS-CRM197. AhpC is a peroxiredoxin involved in oxidative stress reduction and is a potential protective antigen. To facilitate our studies and maximize safety in animals, recombinant B. pseudomallei AhpC harboring an active site mutation (AhpC C57G ) was expressed in Escherichia coli and purified using tandem nickel-cobalt affinity chromatography. Immunization of C57BL/6 mice with CPS-CRM197 combined with AhpC C57G stimulated high-titer IgG responses against the CPS component of the glycoconjugate as well as stimulated high-titer IgG and robust interferon gamma (IFN-γ)-, interleukin-5 (IL-5)-, and IL-17-secreting T cell responses against AhpC C57G . When challenged via an inhalational route with a high dose (~27 50% lethal doses [LD 50 s]) of B. pseudomallei, 70% of the immunized mice survived 35 days postchallenge. Collectively, our findings demonstrate that AhpC C57G is a potent activator of cellular and humoral immune responses and may be a promising candidate to include in future melioidosis subunit vaccines. |
